#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.

Polypill Strategy in Secondary Cardiovascular Prevention – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Polypill reduces cardiovascular events in heart attack patients compared to usual care – European Society of Cardiology

Commentaries:

SECURE: Treatment With Polypill Significantly Lowers Risk of Major CV Events – American College of Cardiology

Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention – HCPLive

Related: M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention. (several studies on the subject)